荣誉与大事记

● Keymed has entered into a global exclusive license agreement 

with Astrazeneca for the development and commercialization 

of CMG901, and will receive an upfront payment of $63m 

on transaction, as well as aditional milestone payments of

 up to $1.1bn and tiered royalties up to low double digits; 

● The first subject has been dosed in Phase I clinical trial

of CM369 (CCR8), co-developed by Keymed & InnoCare

● The latest results from the Phase Ia clinical study of CMG901

was presented at the 2023 ASCO GI Cancers Symposium

● The first-stage construction of Keymed's manufacturing 

park has been completed which would provide an additional

capacity of 16000L; the trial operation stage of the first production

line has been started 

● CMG901 has been granted the Breakthrough Therapy 

Designation for the treatment of Claudin 18.2-positive advanced 

Gastric & Gastroesophageal junction cancer by China CDE

● The IND application of CM369, co-developed by Keymed 

and InnoCare has been approved by NMPA

● The IND application of CM310 has been approved by FDA

for the indication in moderate to severe atopic dermatitis

●  The IND application of CM310 for the new indication

in allergic rhinitis (AR) has been approved by CDE

● The first patient has been dosed in Phase I 

clinical trial of CM350 （GPC3 x CD3) 

● CM310 was granted Breakthrough Therapy Designation 

by the CDE for the treatment of moderate to sever atopic dermatitis

● The IND application of CM369, co-developed by Keymed 

and InnoCare has been accepted by NMPA

● CMG901 for the treatment of gastric 

cancer and gastroesophageal junction

 adenocarcinoma was granted the 

Orphan-drug Designation by the FDA.

● FDA granted CMG901 Fast Track

 Designation for unresectable or metastatic

 gastric and gastroesophageal junction 

cancer which have relapsed and/or are 

refractory to approved therapies.

● Keymed Biosciences was included as eligible 

stocks of the Shenzhen-Hong Kong Stock Connect.

● Keymed Biosciences released positive result from 

Phase II clinical trial of CM310 at CRSwNP.

● CM350 was approved for clinical trial by NMPA.

● The first patient was dosed in clinical trial of CM355 

   a CD20xCD3 bispecificantibody developed by a joint

   venture between Keymed and InnoCare called Tiannuojiancheng 

   Biopharma, for the treatment of CD20+ B-cell malignancies.

● CM338 was approved for clinical trial by NMPA.

● CM326 for AD was approved for clinical trial by NMPA.

● Keymed entered into an agreement with CSPC in relation to the 

   exclusive licensing and commercialization of the product CM326 

   in the  treatment of moderate to severe asthma, chronic 

   obstructive pulmonary disease (COPD) and other respiratory

   system diseases.

● The Phase IIb clinical study of  CM310 recombinant humanized 

   monoclonal antibody injection (CM310AD002) has completed

   the analysis of unblinded data with preliminary statistics,

   showing positive results. 

● CM336 was approved for clinical trials by NMPA.

● CM355 was approved for clinical trials by NMPA.

● Keymed Biosciences Inc. was listed on the Main Board 

   of The Stock Exchange of Hong Kong Limited under the stock 

   code “2162”.

● CM326 was approved for clinical trials by NMPA.

● CMG901 was approved for clinical trials by FDA.

● Keymed entered into an agreement with CSPC in relation to the exclusive licensing and commercialization of the product CM310 in the treatment of moderate to severe asthma, chronic  obstructive pulmonary disease (COPD) and other respiratory 

system diseases .

● CMG901 was approved for clinical trials in October and administered to the first patient in December.

● CM313 was approved for clinical trials in November.

● Phase IIb clinical trial was initiated in November to evaluate the effect of CM310 in patients with moderate to severe atopicdermatitis, and phase II trial was initiated in December to evaluatethe effect of CM310 in patients with chronic sinusitis with polyps.

● In May 2020, CM312 was approved for clinical trials by NMPA.

● Phase Ib/IIa clinical trial was initiated in June to evaluate the effect of CM310 in patients with moderate to severe atopic dermatitis.

● CM310 was approved for clinical trials in July, and the phase I trial was initiated in September.

● Established in Chengdu as an innovative medicine R&D company.